Your company account is blocked and you cannot place orders. If you have questions, please contact your company administrator.

Simtuzumab (anti-LOXL2), for ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt various applications, specific to LOXL2, >95%, high purity, Human IgG4SP, Inhibitor of lysyl oxidase like 2

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Features and benefitsView More
  • Host species: Human
  • Species reactivity(Reacts with): Cynomolgus monkey,Human
  • Isotype: Human IgG4SP
  • Conjugation: Unconjugated
Item Number
Ab170556
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab170556-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$59.90
Ab170556-1mg
1mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$267.90
Ab170556-5mg
5mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$657.90
Ab170556-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,047.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product NameSimtuzumab (anti-LOXL2), for ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt various applications, specific to LOXL2, >95%, high purity, Human IgG4SP
SynonymsEC 1.4.3.13 | Lysyl oxidase-like protein 2 | Lysyl oxidase-related protein 2 | Lysyl oxidase-related protein WS9-14
Specifications & PurityCarrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host speciesHuman
SpecificityLOXL2
ApplicationELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeINHIBITOR
Mechanism of actionInhibitor of lysyl oxidase like 2
Product Description

Simtuzumab (anti-LOXL2) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab (anti-LOXL2) can be used for the research of primary sclerosing cholangitis (PSC).

Purity:

>95% (SDS-PAGE&SEC)

Endotoxin Level

< 1.0EU/mg

Product Properties

Antibody TypePrimary antibody
ClonalityRecombinant
IsotypeHuman IgG4SP
Light Chain Typekappa
SDS-PAGE27.3 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 180.0 kDa, under non-reducing conditions.
Purification MethodProtein A purified
Purity>95%
SourceCHO supernatant
FormLiquid
ConcentrationSee COA
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS1318075-13-6

Images

Simtuzumab (anti-LOXL2) (Ab170556) - ELISA
Immobilized hu-LOXL2-his at 2 μg/mL can bind Simtuzumab (anti-LOXL2) (Ab170556) with the EC₅₀ of 38.57 ng/mL.

Simtuzumab (anti-LOXL2) (Ab170556) - SEC
The purity of Simtuzumab (anti-LOXL2) (Ab170556) is more than 95% verified by HPLC.

Associated Targets(Human)

LOXL2 Tchem Lysyl oxidase homolog 2 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences
Lysyl oxidase homolog 2 inhibitorINHIBITORALA3714029Lysyl oxidase homolog 2SINGLE PROTEINHomo sapiens

PubMed: [1]


Lysyl oxidase homolog 2 inhibitorINHIBITORALA3714029Lysyl oxidase homolog 2SINGLE PROTEINHomo sapiens

PubMed: [1]


Certificates

C of A & Other Certificates(BSE/TSE, COO)

Find and download the COA for your product by matching the lot number on the packaging.

2 results found

Lot NumberCertificate TypeDateItem
ZJ23F1001455Certificate of AnalysisOct 26, 2023 Ab170556
ZJ23F1001456Certificate of AnalysisOct 26, 2023 Ab170556

Related Documents

References

1. Rodriguez HM, Vaysberg M, Mikels A, McCauley S, Velayo AC, Garcia C, Smith V.  (2010)  Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor..  J Biol Chem,  285  (27): (20964-74).  [PMID:20439985] [10.1021/op500134e]
2. Nishioka T, Eustace A, West C.  (2012)  Lysyl oxidase: from basic science to future cancer treatment..  Cell Struct Funct,  37  (1): (75-80).  [PMID:22453058] [10.1021/op500134e]
3. Cano A, Santamaría PG, Moreno-Bueno G.  (2012)  LOXL2 in epithelial cell plasticity and tumor progression..  Future Oncol,  (9): (1095-108).  [PMID:23030485] [10.1021/op500134e]
4. Adamali HI, Maher TM.  (2012)  Current and novel drug therapies for idiopathic pulmonary fibrosis..  Drug Des Devel Ther,  (13): (261-72).  [PMID:23055696] [10.1021/op500134e]
5. Tadmor T, Bejar J, Attias D, Mischenko E, Sabo E, Neufeld G, Vadasz Z.  (2013)  The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms..  Am J Hematol,  88  (5): (355-8).  [PMID:23494965] [10.1021/op500134e]
6. Van Bergen T, Marshall D, Van de Veire S, Vandewalle E, Moons L, Herman J, Smith V, Stalmans I.  (2013)  The role of LOX and LOXL2 in scar formation after glaucoma surgery..  Invest Ophthalmol Vis Sci,  54  (8): (5788-96).  [PMID:23821193] [10.1021/op500134e]
7. Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L, Lyman SK, Adamkewicz JI, Smith V, Kaminski N et al..  (2014)  Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression..  Eur Respir J,  43  (5): (1430-8).  [PMID:24177001] [10.1021/op500134e]
8. Martin A, Salvador F, Moreno-Bueno G, Floristán A, Ruiz-Herguido C, Cuevas EP, Morales S, Santos V, Csiszar K, Dubus P et al..  (2015)  Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression..  EMBO J,  34  (8): (1090-109).  [PMID:25759215] [10.1021/op500134e]
9. Smithen DA, Leung LMH, Challinor M, Lawrence R, Tang H, Niculescu-Duvaz D, Pearce SP, Mcleary R, Lopes F, Aljarah M et al..  (2020)  2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth..  J Med Chem,  63  (5): (2308-2324).  [PMID:31430136] [10.1021/op500134e]
10. Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, Evans HR, Gartland A, Erler JT.  (2011)  LOXL2-mediated matrix remodeling in metastasis and mammary gland involution..  Cancer Res,  71  (5): (1561-72).  [PMID:21233336] [10.1021/op500134e]
11. Hajdú I, Kardos J, Major B, Fabó G, Lőrincz Z, Cseh S, Dormán G..  (2018)  Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited..  Bioorg Med Chem Lett,  28  (18): (3113-3118).  [PMID:30098867] [10.1016/j.bmcl.2018.07.001]
12. Saito, H H, Papaconstantinou, J J, Sato, H H and Goldstein, S S..  (1997)  Regulation of a novel gene encoding a lysyl oxidase-related protein in cellular adhesion and senescence..  The Journal of biological chemistry,    (28):   [PMID:9079631]
13. Jourdan-Le Saux, C C and 5 more authors..  (1999)  The LOXL2 gene encodes a new lysyl oxidase-like protein and is expressed at high levels in reproductive tissues..  The Journal of biological chemistry,    (30):   [PMID:10212285]
14. Peinado, Héctor H and 8 more authors..  (2005)  A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression..  The EMBO journal,    (5):   [PMID:16096638]
15. Nusbaum, Chad C and 75 more authors..  (2006)  DNA sequence and analysis of human chromosome 8..  Nature,    (19):   [PMID:16421571]
16. Schietke, Ruth R and 10 more authors..  (2010)  The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1..  The Journal of biological chemistry,    (26):   [PMID:20026874]
17. Kim, Young-Mi YM, Kim, Eun-Cheol EC and Kim, Youngho Y..  (2011)  The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin..  Molecular biology reports,      [PMID:20306300]
18. Barry-Hamilton, Vivian V and 22 more authors..  (2010)  Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment..  Nature medicine,      [PMID:20818376]
19. Moreno-Bueno, Gema G and 16 more authors..  (2011)  Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas..  EMBO molecular medicine,      [PMID:21732535]
20. Bignon, Marine M and 15 more authors..  (2011)  Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane..  Blood,    (6):   [PMID:21835952]
21. Lugassy, Jennie J and 6 more authors..  (2012)  The enzymatic activity of lysyl oxidas-like-2 (LOXL2) is not required for LOXL2-induced inhibition of keratinocyte differentiation..  The Journal of biological chemistry,    (27):   [PMID:22157764]
22. Li, Tian-Yu TY and 8 more authors..  (2012)  Reduced nuclear and ectopic cytoplasmic expression of lysyl oxidase-like 2 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma..  Human pathology,      [PMID:22204712]
23. Xu, Li L and 7 more authors..  (2013)  Post-translational modifications of recombinant human lysyl oxidase-like 2 (rhLOXL2) secreted from Drosophila S2 cells..  The Journal of biological chemistry,    (22):   [PMID:23319596]
24. Millanes-Romero, Alba A and 8 more authors..  (2013)  Regulation of heterochromatin transcription by Snail1/LOXL2 during epithelial-to-mesenchymal transition..  Molecular cell,    (12):   [PMID:24239292]
25. Cuevas, Eva P EP and 5 more authors..  (2014)  LOXL2 catalytically inactive mutants mediate epithelial-to-mesenchymal transition..  Biology open,    (15):   [PMID:24414204]
26. Iturbide, Ane A and 6 more authors..  (2015)  LOXL2 Oxidizes Methylated TAF10 and Controls TFIID-Dependent Genes during Neural Progenitor Differentiation..  Molecular cell,    (4):   [PMID:25959397]
27. Sasaki, Takako T and 10 more authors..  (2016)  Functional consequence of fibulin-4 missense mutations associated with vascular and skeletal abnormalities and cutis laxa..  Matrix biology : journal of the International Society for Matrix Biology,      [PMID:27339457]
28. Herranz, Nicolás N and 12 more authors..  (2016)  Lysyl oxidase-like 2 (LOXL2) oxidizes trimethylated lysine 4 in histone H3..  The FEBS journal,      [PMID:27735137]
29. Cuevas, Eva P EP and 6 more authors..  (2017)  LOXL2 drives epithelial-mesenchymal transition via activation of IRE1-XBP1 signalling pathway..  Scientific reports,    (23):   [PMID:28332555]
30. Zhang, Xi X and 5 more authors..  (2018)  Crystal structure of human lysyl oxidase-like 2 (hLOXL2) in a precursor state..  Proceedings of the National Academy of Sciences of the United States of America,    (10):   [PMID:29581294]

Solution Calculators